Navigation Links
Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
Date:2/27/2008

SOUTH SAN FRANCISCO, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today that John P. McLaughlin, the company's chief executive officer, will present at the Susquehanna Financial Group SIGnificant Investment Options in Healthcare Conference in New York City on March 5, 2008 at 2:30 pm EDT.

To access the live webcast or the subsequent archived recording, log on to http://www.anesiva.com, go to the Investors page, and click on Events. Please connect to Anesiva's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... San Francisco, California (PRWEB) October 01, 2014 ... grant from the National Science Foundation to expand their ... approaches to build and modify DNA. The Small Business ... help commercialize the “j5” technology under exclusive license from ... the Joint BioEnergy Institute , an LBNL laboratory ...
(Date:9/30/2014)... 2014 Applying a well-known optical phenomenon called ... University has demonstrated the ability to "paint" ultra-thin ... holds promise for making future, flexible electronic devices, ... of next-gen rocket ships and spacecraft with extremely ... oil in water, it becomes iridescent, revealing a ...
(Date:9/30/2014)... 30, 2014 Shimadzu Scientific Instruments ... easy-to-use and highly precise tool for measuring displacement ... elongation. With 1000-mm maximum movement distance, the DSES-1000 ... a gauge length of 10 mm. In addition, ... above 50-mm stroke and within +/- 100 µm ...
(Date:9/30/2014)... 30, 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ... has received a Canadian Patent for Inhibition or ... patent includes claims using thymosin beta 4, various ... for these purposes.  The patent will expire in ... ( www.regenerx.com ) RegeneRx is ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... Ind. - Researchers are edging toward the creation ... of ultra-efficient transmission of light, with potential applications ... The metamaterial - layers of silver and titanium ... dramatically changes the properties of light. The light ...
... CRANBURY, N.J., May 25, 2012  Oncobiologics, Inc. announced ... positions with established biopharmaceutical industry experts. Stephen J. ... and Vincent J. Benn, Ph.D. has joined the ... The company also announced its new Scientific Advisory ...
... ANAHEIM, Calif., May 24, 2012 Questcor Pharmaceuticals, Inc. (NASDAQ: ... present at the Jefferies 2012 Global Healthcare Conference in New ... 8:00 a.m. ET. A live webcast and subsequent ... http://ir.questcor.com/events.cfm .  The replay will be available for approximately 90 ...
Cached Biology Technology:'Metamaterials,' quantum dots show promise for new technologies 2Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board 2Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory Board 3Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference 2
(Date:9/30/2014)... the environmental effects of moorland burning is published today ... with the aim of relieving tensions on both sides ... EMBER (Effects of Moorland Burning on the Ecohydrology of ... moorland, which is practised predominantly to support red grouse ... peat hydrology, peat chemistry and physical properties, river water ...
(Date:9/30/2014)... The most comprehensive assessment conducted by the Ocean ... out of 100 in overall health. In addition, ... Antarctic and the 15 ocean regions beyond national ... maintaining a healthy climate, safeguarding biodiversity and providing ... update of the index, a partnership led by ...
(Date:9/30/2014)... Calif. The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama,s BRAIN (Brain Research ... research effort to revolutionize our understanding of the ...
Breaking Biology News(10 mins):Grouse moor burning causes widespread environmental changes 2Rating the planet's oceans 2Rating the planet's oceans 3NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
... (ODS) at the National Institutes of Health (NIH) announces ... Bibliography of Significant Advances in Dietary Supplement Research. The ... by government, industry, and academic institutions, as well as ... of laboratory, human studies, and observational studies in the ...
... powerful antioxidant in green tea may prevent or delay ... Georgia researchers say. Researchers were testing EGCG, green ... 1 diabetes and primary Sjogren,s syndrome, which damages moisture-producing ... study focused on Sjogren,s syndrome, so learning that EGCG ...
... Washington, DCGeorgetown University Medical Center and Oak ... between the institutions that formalizes their research ... researchparticularly in the areas of structural biology, ... biology. The Comprehensive Research and Development ...
Cached Biology News:Annual Bibliography of Significant Advances in Dietary Supplement Research 2007 2Green tea may delay onset of type 1 diabetes 2Green tea may delay onset of type 1 diabetes 3GUMC and Oak Ridge National Labs announce unique research partnership 2GUMC and Oak Ridge National Labs announce unique research partnership 3
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
... Anti-Natural Killer Cell Receptor-P1, clone ... Hybridoma produced by ... BALB/c mice immunized (BALB/c X ... cells and mouse myeloma cellline. ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Biology Products: